Existing evidence indicates that anti-VEGF drugs combined with surgery can increase the short-term success rate of neovascular glaucoma patients (Zhou et al., 2023), but attention should still be paid to intraocular pressure fluctuations caused by long-term repeated injections (de Vries et al., 2020; Vilares-Morgado et al., 2023). The gene discussed is VEGFA; the disease is neovascular glaucoma.